Cardiol Therapeutics Inc.
CRDL
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -28.61% | -27.99% | 3.52% | -1.97% | 12.45% |
| Total Depreciation and Amortization | -10.27% | 1.07% | 10.11% | 10.02% | 8.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 272.65% | 411.74% | 1,236.87% | 26,861.97% | 257.21% |
| Change in Net Operating Assets | -74.04% | -161.66% | 105.66% | 4.67% | -109.20% |
| Cash from Operations | 1.72% | 17.53% | 27.23% | 17.52% | 10.29% |
| Capital Expenditure | 67.23% | 74.50% | 77.51% | 77.02% | 15.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 67.23% | 74.50% | 77.51% | 77.02% | 15.30% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 25.00% | 25.00% | 8.33% | -0.91% | -2.41% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 32,934.88% | 344.15% | 325.67% | 162.32% | 0.97% |
| Foreign Exchange rate Adjustments | 143.68% | -81.80% | -86.68% | -3.23% | -72.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.68% | 2.06% | 18.71% | 18.78% | 3.50% |